Bimodal antibody-titer decline following BNT162b2 mRNA anti-SARS-CoV-2 vaccination in healthcare workers of the INT – IRCCS “Fondazione Pascale” Cancer Center (Naples, Italy)

Table 3 Vaccine immune response in previously infected and not previously infected cohorts of healthcare providers’ diluted samples

	Median (IR) BAU/mL
	T0	T1	T2 I	T2 II	T3	T6	T9	T boost
Previously infected subjects	207.4	7706.0	10,256.0		2694.0	1685.0	1103.0	52,694.5
	(108.5–244.2)	(7152.0–9220.5)	(9442.5–11,198.5)		(2661.0–2908.0)	(1623.5–> 1745.5)	(1069.0–1221.5)	(51,223.8–54,165.3)
	n = 3	n = 3	n = 3		n = 3	n = 3	n = 3	n = 2
Not previously infected subjects	< 0.4	52.3	4290.0	1794.5	947.2	605.0	481.8	33,419.5
		(30.7–81.0)	(3635.0–4844.3)	(1426.8–2381.0)	(671.8–1325.0)	(410.2–824.6)	(315.9–625.3)	(22,103.3–54,130.8)
	n = 20	n = 20	n = 20	n = 20	n = 20	n = 20	n = 16	n = 14

Previously infected subjects = subjects previously infected with SARS-CoV-2, Not previously infected subjects = subjects not infected with SARS-CoV-2, n = number of subjects, median = median of anti-SARS-CoV-2 S titers, IR = Interquartile Range of anti-SARS-CoV-2 S titers, For previously infected subjects: T0 = baseline pre-vaccination after SARS-CoV-2 infection, T1 = 8 days after the unique dose, T2 I = 1 month after the unique dose, T3 = 3 months after the unique dose, T6 = 6 months after the unique dose, T9 = 9 months after the unique dose, T boost = 8 days after the administration of a further boost dose. For not infected subjects: T0 = baseline pre-vaccination, T1 = 20 days after the first dose, T2 I = 8 days after the second dose, T2 II = 1 month after the second dose, T3 = 3 months after the second dose, T6 = 6 months after the second dose, T9 = 9 months after the second dose, T boost = 8 days after the administration of boost dose

ISSN: 1750-9378